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ABSTRACT
Epstein-Barr virus (EBV)-encoded BamHI-A rightward frame 1 (BARF1) is 
a putative viral oncogene in EBV-infected stomach cancer. The aim of the present 
study was to investigate BARF1-induced cellular protein and microRNA alterations. 
In this study, BARF1-expressing stomach cancer cells showed a high rate of 
proliferation, high levels of NFκB, and miR-146a upregulation, which was reversed 
by NFκB knockdown. During BARF1-induced NFκB upregulation, hCSF1 receptor 
level was unchanged. Knockdown of BARF1 in the naturally EBV-infected YCCEL1 
stomach cancer cells suppressed cell proliferation, and downregulated NFκB and 
miR-146a. SMAD4 was identified as a miR-146a target and was downregulated in 
BARF1-expressing cells, whereas SMAD4 expression was restored by anti-miR-146a. 
Knockdown of BARF1 in YCCEL1 cells upregulated SMAD4, and this effect was reversed 
by miR-146a overexpression. Transfection of BARF1-expressing cells with pCEP4-
SMAD4 abolished the cell proliferating effect of BARF1. In stomach cancer tissues, 
miR-146a was expressed at higher levels, and more frequent NFκB nuclear positivity 
immunohistochemically, but not of SMAD4 nuclear loss was found in the EBV-positive 
group compared with the EBV-negative group. In conclusion, EBV-encoded BARF1 
promotes cell proliferation in stomach cancer by upregulating NFκB and miR-146a 
and downregulating SMAD4, thereby contributing to EBV-induced stomach cancer 
progression.
INTRODUCTION
In 2014, molecular analytic data from The Cancer 
Genome Atlas (TCGA) (http://cbioportal.org) corroborated 
that Epstein-Barr virus (EBV)-associated stomach cancer 
is a specialized subset of stomach cancer [1]. EBV is 
responsible for various human lymphoid and epithelial 
malignancies [1, 2, 3] including EBV-infected stomach 
cancer, which was first reported in 1990 [4]. Currently, 
stomach cancer is the most frequent EBV-associated 
malignancy [5, 6]. Stomach cancer caused by EBV 
infection accounts for approximately 5–10% of all stomach 
cancers worldwide irrespective of cancer incidence [1, 
5–13]. Over the last 25 years, accumulating evidence 
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has shown that EBV infection may directly contribute 
to the development of stomach cancer. EBV-positive 
gastric carcinomas are characterized by the monoclonal 
proliferation of EBV-infected cancer cells [14], global 
CpG island methylation of cancer-related genes [15], 
unique methylation patterns leading to CDKN2A (p16) 
downregulation [1, 16], and hyperactive T-cell activation 
[1, 11]. In addition, EBV-positive stomach cancer shows 
characteristic clinicopathological features, including 
a higher prevalence in male patients, predominant 
localization to the proximal stomach, a tendency towards a 
poorly differentiated histologic type and a diffuse Lauren-
type, the presence of lymphoid stroma [1, 9–11], and a 
unique cellular protein expression profile [12].
The mechanism by which EBV causes stomach 
cancer remains unclear. EBV-encoded BamHI-A rightward 
frame 1 (BARF1) was suggested to function as a viral 
oncogene (oncogenic initiator or oncogenic cofactor) 
in EBV-positive stomach cancer [5, 17–19]. It has been 
demonstrated that BARF1 exists in all of EBV-positive 
stomach cancer tissues with a specialized BARF1-
nucleic acid sequence-based amplification (NASBA) 
method using frozen tissue [19]. Wei et al first described 
recombinant BARF1-induced oncogenic activities, such 
as the tumorigenic transformation of mouse fibroblasts 
and tumor formation in new-born rats [20]. BARF1 has 
sequence homology with colony stimulating factor-1 
receptor (hCSF1 receptor), and BARF1 binds to hCSF1 
(macrophage-colony stimulating factor), similar to the 
binding between hCSF1 and hCSF1 receptor, which 
modulates the fates of immune-related cells such as 
macrophages [18, 21, 22]. EBV-encoded latent membrane 
protein (LMP) 2A is expressed on almost all EBV-positive 
human cancers [23], and the role of LMP2A in EBV-
induced stomach carcinogenesis has been analyzed [6, 10, 
24, 25]. LMP1 is an established viral oncogene in EBV-
infected malignant lymphoma and nasopharyngeal cancer 
[3, 26]; however, LMP1 is not expressed in EBV-infected 
stomach cancer due to promoter methylation [3, 6, 10].
MicroRNAs (miRNAs) are endogenous small 
(19–22 nucleotides) non-coding RNAs that function as 
post-transcriptional regulators of gene expression by 
binding to complementary sites in the 3′ untranslated region 
(3′ UTR) of target mRNAs [27, 28]. miRNAs have been 
implicated in the regulation of various biological processes 
such as inflammation, infection, immune responses and 
tumorigenesis [28–30]. The established viral oncogene 
LMP1 upregulates several cellular miRNAs in different 
human malignancies [31–36]. To the best of our knowledge, 
BARF1-induced cellular miRNA changes have not yet 
to be observed in human malignancies. We previously 
showed that secreted BARF1 upregulated nuclear factor 
κB (NFκB) in an autocrine and paracrine manner in 
stomach cancer [5]. NFκB induces miR-146a expression, 
and the promoter region of miR-146a contains NFκB 
binding sites [29, 33, 37, 38]. Furthermore, miR-146a 
can directly downregulate several genes including 
‘similar to mothers against decapentaplegic homologue 
4ʹ (SMAD4) [39, 40], STAT-1, and IRF-5 [29]. Of these, 
the SMAD4 protein is related to NFκB activity [41, 42]. 
SMAD4 is a central mediator of the transforming growth 
factor beta (TGFβ) signaling pathway. In this pathway, 
TGFβ activation leads to the formation of a heteromeric 
complex between activated SMAD2/ SMAD3 and 
SMAD4, which translocates into the nucleus, and affects 
transcriptional activity [43–45]. The involvement of 
SMAD proteins in EBV-associated oncogenesis has been 
described previously. EBV-encoded LMP1 antagonizes the 
TGFβ-SMAD pathway through NFκB signaling [41, 46], 
and EBV-encoded EBNA1 suppresses the interaction of 
SMAD2 with SMAD4 [47].
The objective of the present study was to investigate 
EBV-encoded BARF1-induced changes such as cell 
proliferation and cellular miRNA and protein expression.
RESULTS
Secreted BARF1 was detected in BARF1-
expressing SNU 601 cells
BARF1 transcripts were detected in BARF1-
expressing cells (SNU601 BARF1 and SNU216 BARF1) 
and in the naturally EBV-infected stomach cancer cell lines 
SNU719 [7, 8] and YCCEL1 [48], but not in SNU601 and 
SNU216 mock cells (transfected with an empty vector) 
(Figure 1A). BARF1 protein was almost undetectable 
in untreated SNU601 BARF1 cells and weakly detected 
in untreated SNU216 BARF1, SNU719 and YCCEL1 
cells; however, BARF1 accumulated in cells treated with 
Brefeldin A (to block protein secretion), suggesting that 
translated BARF1 is mainly secreted (Figure 1B).
BARF1 promoted stomach cancer cell 
proliferation
Both SNU601 BARF1 cells and SNU 216 BARF1 
cells showed higher rates of cell proliferation than their 
mock cells (P < 0.05; Figure 1C). Conversely, YCCEL1 
cells transfected with siRNA against BARF1 (siBARF1) 
showed a lower rate of cell proliferation than scrambled 
siRNA (siSCR)-transfected YCCEL1 cells (Figure 1C).
BARF1 upregulated miR-146a-5p in an NFκB-
dependent manner
To examine the mechanism underlying the 
cell proliferation effect of BARF1, we analyzed the 
potential role of NFκB. NFκB luciferase activity was 
higher in SNU601 BARF1 cells than in SNU601 
mock cells (P < 0.05), and NFκB activity was lower in 
siBARF1-transfected YCCEL1 cells than in scrambled 
siRNA-transfected control YCCEL1 cells (P < 0.01) 
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(Figure 2A). The levels of phospho-hCSF1 receptor 
and hCSF1 receptor were unaltered irrespective of 
BARF1 presence or knockdown, while BARF1 induced 
NFκB and miR-146a-5p upregulation (Figure 2B). 
We then examined the association of miR-146a-5p, a 
cellular miRNA, with NFκB. miR-146a-5p levels were 
significantly higher in SNU601 BARF1 cells than in 
SNU601 mock cells (P < 0.01), and miR-146a-5p was 
downregulated in siBARF1-transfected YCCEL1 cells 
compared with scrambled siRNA-transfected control 
(P < 0.01) (Figure 2C). Transfection of SNU601 BARF1 
cells with NFκB RelA-specific siRNA suppressed the 
BARF1-induced upregulation of miR-146a-5p (Figure 
2D). These results indicate that BARF1 increased the 
levels of NFκB RelA and upregulated miR-146a-5p 
expression in an NFκB-dependent manner.
Figure 1: EBV BARF1 protein was mainly secreted and promoted cell proliferation. (A) BARF1 mRNA was detected 
in SNU601 BARF1 and SNU216 BARF1 cells (stable transfection with BARF1) and in naturally Epstein-Barr virus (EBV)-infected 
stomach cancer cells (SNU719 and YCCEL1), whereas it was undetectable in SNU601 mock cells and SNU216 mock cells. (B) As seen 
by fluorescence microscopy, BARF1 protein was hardly observed in SNU601 BARF1 cells and was weakly detected in SNU216 BARF1, 
SNU719 and YCCEL1 cells, whereas BARF1 protein accumulated in cells that were treated with Brefeldin A. BARF1 antibody (MAb 6F4) 
was labeled in red, and nuclei were counterstained with DAPI (blue). (C) Cell proliferation was higher in SNU601 BARF1 and SNU216 
BARF1 cells than in SNU601 mock cells and SNU216 mock cells, respectively, and lower in YCCEL1 cells transfected with BARF1-
specific siRNA (siBARF1) than in YCCEL1 cells transfected with scrambled siRNA (siSCR) (*P < 0.05). All experiments were performed 
in triplicate. 
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Figure 2: BARF1 upregulated miR-146a-5p in an NFκB-dependent manner. (A) Cells were transfected with an NFκB-
dependent luciferase reporter together with Renilla luciferase. After 72 h, NFκB activity was determined using a dual-luciferase assay. 
SNU610 BARF1 cells demonstrated higher NFκB transcriptional activity than SNU601 mock cells (*P < 0.05). YCCEL1 cells transfected 
with 20 nM BARF1-specific siRNA (siBARF1) showed lower NFκB transcriptional activity than YCCEL1 cells transfected with scrambled 
siRNA (siSCR) (**P < 0.01). (B) Phospho-hCSF1 receptor and hCSF1 receptor showed similar levels irrespective of BARF1 presence or 
knockdown, whereas NFκB RelA and miR-146a-5p increased in response to BARF1. (C) TaqMan quantitative real-time RT-PCR showed 
higher miR-146a-5p levels in SNU601 BARF1 cells than in SNU601 mock cells or untransfected SNU601 cells (**P < 0.01). Conversely, 
miR-146a-5p expression was markedly decreased in YCCEL1 cells transfected with BARF1-specific siRNA (siBARF1) compared with 
YCCEL1 cells transfected with scrambled siRNA (siSCR) or untransfected YCCEL1 cells (**P < 0.01). (D) SNU601 BARF1 cells were 
transfected with 20 nM NFκB RelA-specific siRNA (siRelA) or scrambled siRNA (siSCR). BARF1-induced miR-146a-5p upregulation 
was neutralized by NFκB RelA inhibition (**P < 0.01). All experiments were performed in triplicate.
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BARF1 downregulated SMAD4 in a miR-146a-
5p-dependent manner, and SMAD4 was a direct 
target of miR-146a-5p in stomach cancer cells
To identify targets of miR-146a-5p, we used the 
prediction algorithm TargetScan Human 6.2 (http://www.
targetscan.org), which showed that the 3ʹ UTRs of 200 
mRNAs contained potential miR-146a-5p target sites. 
Among them, IL-1 receptor-associated kinase-1 (IRAK1) 
and SMAD4 were selected because of their role in NFκB 
activation [41, 42, 50]. Because BARF1 downregulated 
SMAD4 protein but had no effect on the level of IRAK1 
(Supplementary Figure S2), we selected SMAD4 as a 
target of miR-146a-5p for subsequent analyses. miR-
146a-5p knockdown by transfection with anti-miR-146a-
5p restored SMAD4 protein levels in SNU601 BARF1 
cells (Figure 3A). In YCCEL1 cells, siRNA-mediated 
silencing of BARF1 upregulated SMAD4 protein, whereas 
transfection with the miR-146a-5p mimic downregulated 
SMAD4 (Figure 3B). Furthermore, transient transfection 
of SNU601 BARF1 cells with the SMAD4 3ʹ UTR plasmid 
along with miR-146a-5p led to a significant decrease in 
relative luciferase activity, compared with the negative 
control (empty vector) along with miR-146a-5p (Figure 
3C). The levels of SMAD2 and SMAD3 were not affected 
by BARF1 (Figure 3D).
BARF1 downregulated nuclear SMAD4
Immunofluorescence analysis showed that nuclear 
SMAD4 protein levels were decreased in SNU601 BARF1 
cells. Conversely, YCCEL1 cells transfected with siBARF1 
showed increased nuclear SMAD4 protein levels (Figure 
4A). This decrease in nuclear SMAD4 protein levels were 
confirmed via western blotting of nuclear protein extracts 
(P < 0.05) (Figure 4B).
SMAD4 neutralized BARF1-induced cell 
proliferation 
The rate of cell proliferation was lower in SNU601 
BARF1 cells transfected with pCEP4-SMAD4 than in 
SNU601 BARF1 cells transfected with empty vector 
(P < 0.01), indicating that ectopic expression of SMAD4 
counteracted the effect of BARF1 on promoting cell 
proliferation (Figure 4C). These results suggest that 
SMAD4 downregulation is critical for cell proliferation in 
BARF1-expressing cells.
Verification of miR-146a-5p upregulation 
and NFκB immunohistochemical expression 
in EBV-positive stomach cancer tissues
According to the miRNA microarray analysis, 139 
cellular miRNAs were differentially expressed with a 1.5-
fold difference between EBV-positive and EBV-negative 
stomach cancer tissues (Figure 5A). Thirty-one cellular 
miRNAs including miR-146a-5p were upregulated and 108 
were downregulated in EBV-infected versus EBV-negative 
stomach cancer tissues (Supplementary Figure S3). The 
upregulation of miR-146a-5p in EBV-positive stomach 
cancer tissues was validated using TaqMan quantitative 
real-time RT-PCR (Figure 5B). 
Additionally, in stomach cancer tissue surgically 
resected in 2012, miR-146a-5p was highly expressed in 
the EBV-positive stomach cancer group (n = 14) compared 
with the EBV-negative stomach cancer group (n = 19) 
(Figure 5C). Immunohistochemically, NFκB expression 
was more frequently observed with a marginal significance 
(P = 0.080) in the EBV-positive group, but not SMAD4 
loss (Table 1).
SMAD4 nuclear loss tended to be associated with 
poor prognosis in EBV-positive, but not EBV-
negative stomach cancer patients
For the patient survival analysis, we chose stomach 
cancers that were surgically resected in 2000~2005. The 
mean follow-up period for patient outcome was 68 months 
(median: 77 months). Of 328 cases, thirty cases were EBV-
positive and 298 were EBV-negative (Supplementary Table 
S1). Immunohistochemical analysis showed SMAD4 
nuclear loss in 10 of 30 EBV-positive cancer patients, of 
whom five (50% of SMAD4 loss/ EBV-positive) died. 
Meanwhile, SMAD4 nuclear loss was observed in 81 cases 
in the EBV-negative group, of whom 30 patients (37% 
of SMAD4 loss/ EBV-negative) were dead. Statistically, 
the SMAD4 nuclear loss group tended to be associated 
with a worse survival rate compared with the SMAD4 
preservation group among EBV-positive stomach cancer 
patients, but not statistically significant (P = 0.08), and 
SMAD4 showed no prognostic implication among EBV-
negative stomach cancer patients (Table 2 and Figure 6).
DISCUSSION
The results of the present study indicate that EBV-
encoded BARF1 promotes cell proliferation in stomach 
cancer through a mechanism involving NFκB and miR-
146a-5p upregulation and SMAD4 downregulation. 
Previous work from our group showed that NFκB RelA 
protein expression is higher in EBV-positive than in 
EBV-negative stomach cancer [5, 7, 8], and that BARF1 
promotes stomach cancer cell proliferation by upregulating 
NFκB [5]. Since then, we have been further searching for 
the molecular link between BARF1 and cell proliferation. 
The present study showed that BARF1 upregulated NFκB 
and induced NFκB-dependent miR-146a-5p upregulation. 
Currently, no studies have investigated EBV-encoded 
BARF1-induced cellular miRNA alterations; Motsch et al. 
showed that EBV-encoded LMP1 upregulates miR-146a in 
an NFκB-dependent manner [35], which is consistent with 
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Figure 3: BARF1 downregulated SMAD4 in a miR-146a-5p-dependent manner, and SMAD4 was a direct target of 
miR-146a-5p. (A) SMAD4 protein expression in SNU601 BARF1 cells was measured via western blotting after transfection with a miR-
146a-5p inhibitor (anti-miR-146a) or a scrambled miRNA control (miR-control). SMAD4 protein level was downregulated in SNU601 
BARF1 cells, and was restored by miR-146a-5p inhibition (*P < 0.05). (B) YCCEL1 cells (naturally EBV-infected stomach cancer) were 
transfected with 20 nM siRNAs (BARF1-specific or scrambled) and 50 nM miRNAs (miR-146a-5p mimic or miR-control). SMAD4 was 
upregulated in YCCEL1/siBARF1 cells and downregulated by the miR-146a-5p mimic (*P < 0.05). (C) The 8-mer sequence homology 
between miR-146a-5p and the 3′UTR of SMAD4 mRNA is shown. The mRNA transcript sequences were extracted from the website 
(http://www.ensembl.org). The luciferase assay revealed reduced reporter activity after co-transfection of SMAD4 3′UTR and miR-146a-
5p in SNU601 BARF1 cells, compared with co-transfection of a negative control (NC, empty vector) and miR-146a-5p (*P < 0.05). All 
experiments were performed in triplicate. (D) BARF1 downregulated SMAD4 in total cell lysates, but had no effect on SMAD2 or SMAD3 
expression. The bar graph shows the ratio of SMAD normalized to β-actin as determined by optical density measurement (*P < 0.05). All 
experiments were performed in triplicate.
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the results of the present study regarding BARF1-induced 
NFκB/miR-146a upregulation. Unfortunately, the BARF1-
induced NFκB /miR-146a /SMAD4 axis observed in cell 
line was not clearly recapitulated in tissues. BARF1 protein 
is expressed within EBV-positive tumor cells, after that, 
almost completely secreted out of tumor cells [18, 21, 22], 
and this was attested in the present study using a secretion 
blocker in cell lines. Accordingly, it is challenging to 
directly detect BARF1 protein in tissue sample. Instead, 
zur Hausen et al. demonstrated the existence of BARF1 
[18, 21, 22]. in EBV-positive stomach cancer tissue using 
a BARF1 nucleic acid sequence-based amplification 
(NASBA) method [19]; thus, EBV-positive stomach cancer 
is thought to belong to a specialized EBV latency type I 
expressing BARF1 [3]. In addition, there may be limits to 
pursuing BARF1-specific effects on NFκB, miR-146a and 
SMAD4 in tissues, as cancer-related cellular proteins are 
likely controlled by intricate pathways in cancer tissues. As 
such, BARF1 may have a restricted effect on NFκB, miR-
146a and SMAD4 in tissue.
The effect of BARF1 on NFκB and miR-146a in 
SNU601 BARF1 and naturally EBV-infected YCCEL1 
cells may occur via intracellular signaling, rather than 
via the secretory pathway. The activation effect seems 
to be mediated by the N-terminal 1-20 AA domain of 
BARF1, which remains intracellular [18]. This idea is 
supported by the fact that NFκB and miR-146a levels 
decreased dramatically following BARF1-specific siRNA 
transfection in the present study. The hCSF1 receptor 
might not be involoved in the process of BARF1-
induced NFκB and miR-146a-5p upregulation, because 
phospho-hCSF1 receptor and hCSF1 receptor levels were 
unchanged during NFκB and miR-146a-5p upregulation 
(Figure 2), and hCSF1 receptor blocking did not influence 
BARF1-induced NFκB upregulation in the present study 
(Supplementary Figure S4). 
The present study suggests that BARF1 suppressed 
SMAD4 through NFκB-dependent miR-146a upregulation 
in stomach cancer cells. Previous studies found that 
the established viral oncogene LMP1 inhibits the 
transcriptional activity of SMAD via NFκB activation [46]. 
Moreover, the present study identified SMAD4 as a direct 
target of miR-146a in SNU601 BARF1 cells, providing 
the first experimental evidence in stomach cancer cells. 
Table 2: Differential effect of SMAD4 on patient survival in Epstein-Barr virus-positive and 
Epstein-Barr virus-negative stomach cancer 
SMAD4 nuclear loss SMAD4 preserved
EBV-positive (n = 30) 10 20 P value
 Dead 5 (50%) 4 (20%) 0.08
 Alive 5 (50%) 16 (80%)
EBV-negative (n = 298) 81 217 P value
 Dead 30 (37%) 85 (39%) 0.76
 Alive 51 (63%) 132 (61%)
Table 1: Comparison of NFκB RelA, miR-146a-5p and SMAD4 between Epstein-Barr virus-
positive and Epstein-Barr virus-negative stomach cancer
EBV-positive EBV-negative
(n = 14) (n = 19) P value
NFκB RelA 0.080
 negative 9 (67%) 17 (90%)
 positive 5 (33%) 2 (10%)
miR-146a-5p 0.033
 mean / median 148.5/102.3    67.4/60.4 
 (range) (38.0 ~ 483.6) (13.0 ~ 146.4)
SMAD4 0.580
 loss 7 (50%) 10 (53%)
 preserved 7 (50%)  9 (47%)
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Figure 4: BARF1-mediated down regulation of nuclear SMAD4, and the effect of SMAD4 on cell proliferation. (A) 
Immunofluorescence was visualized via confocal microscopy. BARF1 attenuated nuclear SMAD4 in SNU601 BARF1 cells, whereas 
BARF1 inhibition augmented nuclear SMAD4 in YCCEL1 cells transfected with siBARF1. Cells were labeled with SMAD4 antibody 
(green), and nuclei were counterstained with DAPI (blue). (B) Western blotting of nuclear extracts confirmed the BARF1-mediated 
downregulation of nuclear SMAD4 (*P < 0.05). TFII B was used as a loading control. (C) SNU601 BARF1 and SNU601 mock cells were 
transfected with pCMV-SMAD4 (SMAD4) or pCMV-empty vector (VECTOR). Cell proliferation was suppressed by pCMV-SMAD4 
transfection compared with cells transfected with empty vector (**P < 0.01). All experiments were performed in triplicate.
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Xiao et al. previously detected miR-146a upregulation in 
stomach cancer cell lines; however, the SMAD4 3ʹ UTR 
luciferase target assay results were obtained in HEK293 
(human embryonic kidney) cells and not in stomach 
cancer cells [51]. Additionally, SMAD4 is a target of miR-
146a in various malignancies, such as leukemia [39] and 
hepatocellular carcinoma [52]. 
The results of the present study suggest that SMAD4 
may have different implication between EBV-positive 
stomach cancer and EBV-negative stomach cancer. 
SMAD4 nuclear loss, as detected by immunohistochemical 
staining in stomach cancer tissues, tended to be associated 
with poor survival rates in EBV-positive stomach cancer 
patients. Although the role of SMAD4 in the prognosis 
of EBV-positive stomach cancer patients has not been 
described previously, several reports have shown that 
SMAD4 loss is associated with poor prognosis in advanced 
stomach cancer patients [53–55]. In addition, SMAD4 
functions as a tumor suppressor gene in stomach cancer 
[53, 56]. The altered SMAD4 nuclear accumulation that 
Figure 5: miRNA microarray expression profile and validation of miR-146a-5p level in surgically resected stomach 
cancer tissues. (A) Heat map and hierarchical clustering of miRNA expression showed a clear contrast between EBV-positive and EBV-
negative cancer groups, with 31 miRNAs being upregulated including miR-146a-5p. Tissue samples are denoted as EBV(+) 1 and EBV(+) 2 
for EBV-infected stomach cancer tissues and EBV(-) 3 and EBV(-) 4 for EBV-negative stomach cancer cases. The upper horizontal section 
represents human cellular miRNAs (hsa-miRNAs), and the lower horizontal section indicates EBV miRNAs (ebv-miRNAs). The red 
color indicates the expression of miRNAs in the sample, and green indicates absent or downregulated miRNAs. (B) TaqMan quantitative 
real-time RT-PCR was used to validate miRNA microarray data. miR-146a-5p levels were higher in EBV-positive stomach cancer tissues 
than in EBV-negative stomach cancer tissues (*P < 0.05). (C) TaqMan quantitative real-time RT-PCR for miR-146a-5p was performed 
for an additional 14 cases of EBV-positive stomach cancer tissues and the other additional 19 EBV-negative stomach cancer tissues. The 
miR-146a-5p level in the EBV-positive stomach cancer group was higher than that in the EBV-negative stomach cancer group (*P < 0.05). 
RNU6B was used to normalize miR-146a-5p expression.
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was detected in the present study supports the idea that 
SMAD4 is active and affects transcriptional activity 
when localized to the nucleus [43, 45]. With regard to a 
mechanism of SMAD4 nuclear loss, various mechanisms 
including dysregulation of nucleocytoplasmic shuttling, 
loss of heterozygosity, promoter hypermethylation and 
proteasome degradation are found in gastric carcinomas 
[53]. In particular, van Rees et al. reported that allelic 
loss of chromosome 18q (involving SMAD4 locus) 
was significantly less frequent in EBV-positive gastric 
carcinomas than in EBV-negative gastric carcinomas, 
which might be compensated for by a higher frequency 
of gene inactivation through promotor hypermethylation 
in EBV-positive gastric carcinomas [57].
In conclusion, EBV-encoded BARF1 promotes 
stomach cancer cell proliferation through a mechanism 
involving the upregulation of NFκB and miR-146a and 
the downregulation of SMAD4. These results may help 
explain the molecular mechanisms of EBV-infected 
stomach cancer progression. Moreover, SMAD4 loss may 
be useful as a negative prognostic factor in EBV-positive 
stomach cancer patients.
MATERIALS AND METHODS
Cell culture and reagents
SNU719 (stomach cancer cell line naturally 
infected with EBV), SNU601 and SNU216 (EBV-
negative stomach cancer cell lines) were purchased from 
the Korean Cell Line Bank (Seoul, Korea). Another 
EBV-infected stomach cancer cell line, YCCEL1, was 
supplied by Dr. Rha [48]. Stable BARF1-expressing 
stomach cancer cells, SNU601 BARF1 [5] and SNU216 
BARF1 cells were established. In brief, BARF1 was 
cloned from the naturally EBV-infected stomach cancer 
cell line SNU719. A pCMV-Tag 2B/flag/BARF1 plasmid 
was introduced into EBV-negative stomach cancer 
cells (SNU601 and SNU216) and transfectants were 
selected with G418 (Invitrogen, Carlsbad, CA, USA) 
(Supplementary Figure S1). Cells were maintained in 
RPMI 1640 medium (Gibco BRL, Rockville, MD, USA) 
supplemented with 10% fetal bovine serum and antibiotics 
(100 U/mL penicillin and streptomycin) at 37°C in a 5% 
CO2 atmosphere. Brefeldin A was used to inhibit protein 
transport from the endoplasmic reticulum to the Golgi 
apparatus (Sigma-Aldrich, St. Louis, MO, USA). 
RNA isolation and reverse transcription-
polymerase chain reaction (RT-PCR)
Total cellular RNA was prepared using an RNeasy 
Mini Kit (Qiagen, Hilden, Germany). Extracted RNA 
was treated for 20 min at 37°C with 10 units of DNase 
I (Roche, Basel, Switzerland) in the presence of RNase 
inhibitor (Roche) to remove residual genomic DNA. 
After inactivation at 75°C for 10 min, RNA samples 
were purified with an RNeasy Mini Kit (Qiagen) 
Figure 6: Different clinical implication of SMAD4 expression in EBV-positive and EBV-negative stomach cancer 
patients. (A) Representative microscopic images of the histologic features of EBV-positive stomach cancer tissues. In-situ hybridization for 
EBV-encoded small RNAs (EBER) showed black signals in almost all of the cancer cell nuclei. NFκB and SMAD4 immunohistochemistry 
was evaluated only nuclear staining of cancer cells. (B) Kaplan-Meier survival curves. The ‘SMAD4 loss’ group (solid line) tended to show 
a worse survival rate than the ‘SMAD4 preserved’ group (dotted line) among EBV-positive cancer patients (P = 0.08), whereas SMAD4 
had no prognostic significance in EBV-negative patients.
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according to the manufacturer’s recommendations. 
cDNA was synthesized from 1 µg of total RNA 
(extracted from each sample) using a high fidelity RT-
PCR system. The forward and reverse primers for 
cDNA amplification were as follows: BARF1 forward, 
5′-CGGGATCCATGGCCAGGTTCATC-3′, and reverse, 
5′-CCGCTCGAGTCATTGCGACAAGTAT-3′; GAPDH 
forward, 5′-GAGTCAACGGATTTGGTCGT-3′, and 
reverse, 5′-TTGATTTTGGAGGGATCTCG-3′. The PCR 
conditions were as follows: 30 cycles each of denaturation 
at 94°C for 30 sec, annealing at 54°C for 30 sec, and 
extension 72°C for 1 min. PCR products were analysed on 
2% agarose gels.
Immunofluorescence assay 
Cells seeded on coverslips were fixed for 10 min in 
4% paraformaldehyde in 10 mmol/L piperazine- N,N`-
bis (2-ethanesulfonic acid) (PIPES), pH 6.8, 10 mmol/L 
NaCl, 300 mmol/L sucrose, 3 mmol/L MgCl2, and 
2 mmol/L EDTA. Cells were permeabilized for 10 min 
in Tris-buffered saline (TBS) with 0.75% Triton X-100 
and blocked for 10 min in 5% bovine serum albumin and 
0.1% Triton X-100 in TBS. Cells were then incubated 
with antibodies against BARF1 (MAb 6F4, 1:100) [5] 
and SMAD4 (sc-7966, 1:200 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and Alexa Fluor 488 goat anti-
mouse IgG (H+L) secondary antibody (Invitrogen). Nuclei 
were counterstained with 4ʹ,6-diamidino-2-phenylindole 
(DAPI) (1 μg/mL). Stained cells were visualized on a Zeiss 
Observer.Z1 fluorescence microscope or a Zeiss LSM710 
confocal system (Carl Zeiss Meditec, Jena, Germany).
Cell proliferation assay
Cells were seeded into 96-well plates, treated as 
indicated, and incubated with the cell proliferation reagent 
Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, 
Kumamoto, Japan) (10 µL of CCK-8) for 2 h. Absorbance 
was measured at 450 nm on a spectrophotometer (Spectramax 
190; Molecular Devices, Sunnyvale, CA, USA).
Quantitative real-time RT-PCR
Total cellular RNA including miRNA was isolated 
using the miRNeasy Mini Kit (Qiagen). miRNA cDNA 
synthesis was carried out with 10 ng of total RNA from 
each sample using the TaqMan MicroRNA Reverse 
Transcription Kit (Ambion Life Technologies, Grand 
Island, NY, USA). TaqMan quantitative real-time RT-
PCR analysis was performed with an ABI 7900 Real-Time 
PCR System using the TaqMan miRNA assay (Applied 
Biosystems, Foster City, CA, USA) with the hsa-miR-
146a-5p (MIMAT0000449) primer set according to the 
manufacturer’s protocol. RNU6b (Applied Biosystems) 
was used as a loading control in the TaqMan microRNA 
assay.
siRNA, miRNA and plasmid transfection
NFκB RelA-specific small interfering RNA 
(siRNA) and BARF1-specific siRNA (5′-GAGCCUCGGU 
CCAGAGAUUUU-3′) were synthesized by Dharmacon 
RNA Technologies (Dharmacon, Lafayette, CO, USA). 
A scrambled siRNA (Dharmacon) containing a random 
sequence of nucleotides without known specificity was 
used as a negative control.
The miR-146a-5p mimic (hsa-miR-146a-5p; 
MC10722), miR-146a-5p inhibitor (hsa-miR-146a-5p; 
MH10722), and scrambled miRNA control (miR-control) 
were purchased from Ambion Applied Biosystems 
(Ambion Life Technologies). Transfections were 
performed using Lipofectamine 2000 (Invitrogen). Cells 
were transfected with miR-146a-5p mimic, miR-146a-5p 
inhibitor, or miR-control at a final concentration of 50 nM. 
The pCEP4-SMAD4 plasmid was obtained from the 
nonprofit plasmid repository Addgene (Cambridge, MA, 
USA) and was donated by Dr. Vogelstein [49].
Western blot and densitometric analyses 
Protein concentrations were determined using a 
BCA protein assay kit (Merck, Gibbstown, NJ, USA). 
Proteins were separated by SDS-PAGE gels topped by 
a 5% stacking gel and then transferred onto reinforced 
PVDF membranes (Millipore, Bedford, MA, USA). 
After incubation to block non-specific sites, blots were 
incubated overnight with primary antibodies against 
NFκB RelA (sc-109, 1:500, Santa Cruz Biotechnology), 
phospho-hCSF1 receptor (1:1000, Cell Signaling, Beverly, 
MA, USA), hCSF1 receptor (1:1000, Cell Signaling), 
SMAD2 (D43B4, 1:1000, Cell Signaling), SMAD3 
(C67H9, 1:1000, Cell Signaling), and SMAD4 (B-8, sc-
7966, 1:1000, Santa Cruz Biotechnology) at 4°C. Blots 
were then washed and incubated for 30 min at room 
temperature with a horseradish peroxidase-conjugated 
anti-mouse secondary antibody (Abcam, Cambridge, UK). 
The antigen-antibody complexes were visualized using 
ECL-staining (Amersham, Arlington Heights, IL, USA) 
and expose to X-ray film. Antibodies against transcription 
factor IIB (sc-23875, 1:2000, Santa Cruz Biotechnology) 
and β-actin (AC -15, 1:10000, Abcam) were used to verify 
equal loading and transfer of nuclear and total proteins, 
respectively. Developed films were imaged using a GS-
700 Imaging Densitometer (Bio-Rad, Hercules, CA, USA) 
and processed with Corel Photo Paint 7.0 to adjust image 
brightness and contrast. Densitometric evaluation was 
performed using Molecular Analyst Software (Bio-Rad), 
and normalization was performed using the corresponding 
controls depending on the specific analysis.
Preparation of nuclear extracts 
Cells were resuspended in 100 μL of lysis buffer 
A (10 mmol/L Tris, pH 8.0, 60 mmol/L NaCl, 1 mmol/L 
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EDTA, 1 mmol/L dithiothreitol, 0.1% Nonidet P-40 and 
1 mmol/L phenylmethylsulfonyl fluoride) and incubated 
on ice for 5 min. Nuclear pellets were immediately 
washed in 1 mL of lysis buffer A without Nonidet P-40, 
centrifuged, and resuspended in 50 μL of buffer B (200 
mmol/L HEPES, pH 7.9, 0.75 mmol/L spermidine, 
0.15 mmol/ L spermine, 0.2 mmol/L EDTA, 2 mmol/L 
EGTA, 2 mmol/ L dithiothreitol, 20% glycerol, 1 mmol/L 
phenylmethylsulfonyl fluoride, and 0.4 M NaCl).
Luciferase activity assay  
To measure NFκB activity, cells were transfected 
with a cis-reporter plasmid containing the luciferase 
reporter gene linked to five tandem NFκB binding 
sites (0.8 μg, pNFκB Luc vector; Stratagene, La Jolla, 
CA, USA) using Lipofectamine 2000 (Invitrogen). A 
Renilla luciferase control reporter vector (0.04 μg, pRL-
SV40:E2231; Promega, Madison, WI, USA) was co-
transfected to normalize for transfection efficiency. After 
72 h, luciferase activity was measured using a Dual-
Luciferase Reporter Assay System kit (Promega) and was 
normalized to Renilla luciferase activity.
For the SMAD4 3ʹUTR assay, SNU601 BARF1 cells 
were seeded into 12-well plates one day before transfection, 
and then co-transfected with 0.8 μg of pEZX-MT06 vector, 
containing either the SMAD4 3ʹUTR Renilla/firefly dual-
luciferase reporter plasmid (GeneCopoeia, Rockville, MD, 
USA) or empty vector (GeneCopoeia), along with 50 nM 
of miR-146a-5p mimic or scrambled miRNA control (miR-
control). After 48 h, luciferase activity was measured using 
the dual-luciferase assay kit (Promega). Renilla luciferase 
activity was normalized to firefly luciferase activity. All 
assays were conducted in triplicate, and each transfection 
with reporter plasmid was carried out on a different day.
miRNA microarray and data analysis
Formalin-fixed paraffin-embedded tissue samples 
were cut with a microtome. Cut sections were placed 
in 1.5 mL tubes, and total RNA including miRNA 
was extracted using the miRNeasy FFPE kit (Qiagen) 
according to the manufacturer’s instructions. The tissue 
lysate was treated with DNase I (Roche) to exclude 
DNA contamination. The miRNA expression profiles 
of stomach cancer tissue were established using the 
SurePrint G3 Human miRNA Microarray, Release 16.0, 
8x60K (Agilent Technologies, Santa Clara, CA, USA), 
which is based on miRBase v16.0 (http://www.mirbase.
org) and contains a total of 1205 human and 144 human 
viral miRNAs. All procedures were performed according 
to the manufacturer’s recommendations. To analyse the 
differentially expressed miRNAs, quantile normalization 
was performed to standardize the data across the samples. 
Two cases of EBV-positive stomach cancer were grouped 
and analyzed against another two cases of EBV-negative 
stomach cancer using a fold-change cut-off of 1.5. 
Hierarchical clustering was then performed using the 
Euclidean distance metric and the complete linkage rule.
RNA in-situ hybridization and 
immunohistochemistry of surgically resected 
stomach cancer tissues
For patient prognosis study, we used formalin-
fixed paraffin-embedded tissues from 328 stomach 
cancer patients who had undergone surgery at the Seoul 
National University Boramae Hospital. In total, 30 cases 
of EBV-positive stomach cancer were included in the 
study: 13 (4.2%) were from 311 consecutive surgeries 
that were performed between 2000 and 2005, and 17 were 
obtained from surgical cases in 2006~2010. For miRNA 
study, more recent formalin-fixed paraffin-embedded 
tissues should be needed. Accordingly, we selected 
stomach cancer tissues surgically resected in 2012, in 
which there were 14 EBV-positive and 19 EBV-negative 
cases. The retrospective study protocol was reviewed and 
approved by the Institutional Review Board of the Seoul 
National University Boramae Hospital under conditions 
of anonymity (IRB No. 20110318/06-2011-40/106 & 
20150907/16-2015-124/101).
In-situ hybridization for EBV-encoded small RNAs 
(EBERs) was performed with the Discovery XT automated 
IHC/ISH stainer (Ventana Medical Systems, Tucson, AZ, 
USA), according to the manufacturer’s instructions. A 
fluorescein-conjugated EBV oligonucleotide probe for 
EBERs was used (Novocastra, Newcastle-upon-Tyne, UK). 
Black or dark navy-colored signals at the hybridization 
site, detected by light microscopy, were interpreted as 
EBV-carrying cells. Rarely, reactive lymphocytes showed 
black signals, but only signals within tumor cell nuclei 
were considered positive. All of EBV-positive cases 
showed black signals in almost all cancer cell nuclei.
Immunohistochemistry for NFκB and SMAD4 was 
performed with the Bond-Max automated immunostainer 
(Leica Microsystems, Nussloch, Germany). The tissue was 
incubated with anti-NFκB p65 (C-20) (sc-372, 1:150, Santa 
Cruz Biotechnology) or anti-SMAD4 antibody (B-8, sc-
7966, 1:200, Santa Cruz Biotechnology), and the antigen 
was detected with the Bond Polymer Refine Detection Kit 
DC9800 (Leica Microsystems). Immunohistochemical 
staining was evaluated by two pathologists (M.S.C. & 
S-j.B.). Staining intensity was scored as 0 (no staining), 
1+ (weak intensity), 2+ (moderate intensity), or 3+ (strong 
intensity). For NFκB, 2+ or 3+ staining in ≥ 5% of cancer 
cell nuclei was considered positive [7, 8]. Regarding 
SMAD4, cases showing 2+ or 3+ staining in more than 
10% of the cancer cell nuclei were deemed as ‘SMAD4 
preserved,’ and the remaining cases were defined as 
‘SMAD4 loss’ [58].
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Statistical analysis 
A chi-square test, Pearson’s test, Kendall’s Tau-b 
correlation analyses, Mann-Whitney U test and Kaplan–
Meier survival analysis were performed with IBM® 
SPSS® Statistics 20.0 (IBM Inc., Chicago, IL, USA). A 
P value < 0.05 was considered statistically significant.
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